Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Longeveron Inc. - Class A Common stock (NQ:LGVN)

0.8305 +0.0005 (+0.06%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Longeveron Inc. - Class A Common stock

< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
Longeveron (NASDAQ: LGVN) Announces Positive Top-Line Results For Its Phase 2a Clinical Trial For The Treatment Of Mild Alzheimer's Disease with Lomecel-B™
Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biotech company aiming to address life-threatening and chronic aging-related conditions using cell therapies, continues to make positive progress. 
Via Benzinga
BioMedNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) Eyes ‘Encouraging’ Results from CLEAR MIND Trial
Via Investor Brand Network
Hidden Belly Fat Could Be a Precursor of Alzheimer’s Onset Years Later
Via Investor Brand Network
Earnings Preview: Longeveron
 
Via Benzinga
Longeveron Inc. (NASDAQ: LGVN) Encouraged by Positive Results from Phase 2a Trial in Patients with Mild AD; Explores Paths Forward for the Development of Lomecel-B(TM)
Via Investor Brand Network
Study Links Cat Parasite to Accelerated Frailty in Aging People
Via Investor Brand Network
BioMedNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) Featured in Bell2Bell Podcast
Via Investor Brand Network
BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN; LGVNR) Study Survival Data Reported at AHA’s 2023 Scientific Sessions
Via Investor Brand Network
BioMedNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) Announces 2023 Results, Provides Corporate Update
Via Investor Brand Network
Earnings Scheduled For November 10, 2023
Companies Reporting Before The Bell • Dixie Gr (NASDAQ:DXYN) is estimated to report earnings for its third quarter. 
Via Benzinga
Sex Hormones Could Influence Alzheimer’s Development, Researchers Say
Via Investor Brand Network
BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN; LGVNR) Announces Plans to Release Q3 2023 Financial Report, Host Corporate Update Call
Via Investor Brand Network
Longeveron Inc. (NASDAQ: LGVN) Validates Safety and Therapeutic Potential of its Lomecel-B(TM) Lead Investigational Product in its CLEAR MIND Phase 2a Clinical Trial
Via Investor Brand Network
BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN; LGVNR) Top-Line Results from Phase 2a Trial Spotlighted in Latest NNA Release
Via Investor Brand Network
Nearly A Third Of Japan’s 36 Million Seniors Are At Risk Of Aging Frailty – Could Lomecel-BTM, Longeveron’s (NASDAQ: LGVN) Cell Therapy Help?
--News Direct-- 
Via News Direct
Nearly A Third Of Japan's 36 Million Seniors Are At Risk Of Aging Frailty – Could Lomecel-BTM, Longeveron's (NASDAQ: LGVN) Cell Therapy Help?
Nations all over the world are getting older, but Japan is leading the charge, with nearly a third of its total population over 65 — making Japan the oldest society in the world. 
Via Benzinga
BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN; LGVNR) Closes on $4M Registered Direct Offering
Via Investor Brand Network
Does Bone Marrow Contain The Keys To Curing Alzheimer's? BioTech Announces Promising Results From Clinical Trial
Wa’el Hashad, CEO of Longeveron (NASDAQ: LGVN), was a guest recently on Benzinga’s All-Access. 
Via Benzinga
BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN; LGVNR) Enters into $4M Registered Direct Offering
Via Investor Brand Network
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
Why Accolade Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers Orchard Therapeutics plc (NASDAQ: ORTX) shares climbed 97.7% to $15.98 after the company agreed to be acquired by Japan's Kyowa Kirin for $16.00 per ADS in cash plus an additional contingent... 
Via Benzinga
BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN; LGVNR) Reports Top-Line Results for Phase 2a Lomecel-B Clinical Trial
Via Investor Brand Network
Longeveron's Alzheimer's Candidate Meets Safety Goal In Mid-Stage Study
Longeveron Inc (NASDAQ: LGVN) announced topline results from the Phase 2a trial of its investigational product Lomecel-B for  
Via Benzinga
Longeveron Inc. (NASDAQ: LGVN) Eyeing Global HLHS, in addition to Alzheimer’s Disease, and Aging-Related Frailty Treatment Markets with Lomecel-B(TM), its Lead Investigational Product
Via Investor Brand Network
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.